// App-Quantinova.ai

AB0756 : GUSELKUMAB IMPROVED WORK PRODUCTIVITY AND DAILY ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL

Researchers

Presenter

  • J. Curtis

Principal Investigators

  • I. Mcinnes

  • P. Rahman

  • W. Tillett

  • P. J. Mease

  • A. Kollmeier

  • E. C. Hsia

  • B. Zhou

  • P. Agarwal

  • S. Peterson

  • C. Han

Medical Centers

  • Uni Alabama, Birmingham, United States of America

  • Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, UK

  • Memorial University of Newfoundland, St. John's, NF, Canada

  • Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom

  • Janssen Research & Development, Raritan, United States of America

  • Perelman School of Medicine, Philadelphia, United States of America

  • , Janssen Global Services, LLC, Horsham, PA, United States of America

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Abbvie

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved